GKL-006 / Beijing Gene Key Life Technology - LARVOL DELTA

A Phase I/II clinical study of GKL-006RTU injection. (ChiCTR) - P1/2 | N=12 | Not yet recruiting | Sponsor: Peking Union Medical College Hospital; Peking Union Medical College Hospital

New P1/2 trial • Acute Respiratory Distress Syndrome • Pulmonary Disease • Respiratory Diseases

A Phase I/IIa Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer (clinicaltrials.gov) - P1/2 | N=52 | Active, not recruiting | Sponsor: Beijing Gene Key Life Technology Co., Ltd

New P1/2 trial • Oncology • Pancreatic Cancer • Solid Tumor

GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - P2 | N=48 | Recruiting | Sponsor: Beijing Gene Key Life Technology Co., Ltd | Not yet recruiting ➔ Recruiting | Trial completion date: Oct 2026 ➔ Oct 2027 | Trial primary completion date: Oct 2026 ➔ Sep 2027

Enrollment open • Trial completion date • Trial primary completion date • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - P1 | N=6 | Active, not recruiting | Sponsor: Beijing Gene Key Life Technology Co., Ltd

New P1 trial • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

GKL-006Allo Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=27 | Not yet recruiting | Sponsor: Beijing Gene Key Life Technology Co., Ltd

New P1 trial • Oncology • Solid Tumor

Safety and Efficacy Study of GKL-006RTU in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS) (clinicaltrials.gov) - P1/2 | N=52 | Not yet recruiting | Sponsor: Beijing Gene Key Life Technology Co., Ltd

New P1/2 trial • Acute Respiratory Distress Syndrome • Pulmonary Disease • Respiratory Diseases

GKL-006 Combined With TACE in Treatment of Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - P2 | N=48 | Not yet recruiting | Sponsor: Beijing Gene Key Life Technology Co., Ltd

New P2 trial • Hepatocellular Cancer • Oncology • Solid Tumor

Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy (clinicaltrials.gov) - P2 | N=84 | Recruiting | Sponsor: Beijing YouAn Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor